Earnings Call Intelligence Subscribe
Home › Call Sheets › TMO › Q4'25
Call sheet · Q4'25

Thermo Fisher Scientific (TMO)

Q4'25 earnings call · held 2026-01-29 · compared with the Q3'25 call · management-credibility review
7/12
Disclosure score
4 medium, 3 low flags
Financial quality
Bottom line
The Clario acquisition at 6x revenue screams desperation to accelerate clinical research growth beyond the pedestrian 3-4% organic range they just guided to. While everyone celebrates the biopharma 'high single-digit' growth, the real story is industrial markets quietly recovering faster than expected. The binding constraint isn't demand - it's that their diversified portfolio means they can't fully capitalize on any single end market recovery. Casper's telling quote: 'We're starting out with market conditions roughly the same as last year in aggregate and we don't have the repeat of the roll-off of the pandemic revenue.' Translation: ex-COVID, they're still stuck at 3% organic. My view changes if Q1 organic growth exceeds 1% or if they provide specific Accelerator revenue contribution data by Q2.

The 30-second version

  • Clario acquisition pricing reveals desperate need for clinical research scale
  • BioPharma 'high single-digit' Q4 masks deceleration vs industrial recovery narrative
  • Free cash flow guidance disappointment buried under EPS beat

What changed this quarter

MetricQ3'25Q4'25Change
Revenue$11.12B (+5% YoY)$12.21B (+7% YoY)+200 bps acceleration
Adjusted EPS$5.79 (+10% YoY)$6.57 (+8% YoY)-200 bps deceleration
Adjusted Operating Margin23.3% (+100 bps YoY)23.6% (-30 bps YoY)-130 bps sequential deterioration
Organic Growth3%3%Flat despite easier comps
Life Sciences Solutions Revenue~$2.6B (8% growth)~$3.1B (13% growth)+500 bps acceleration
Analytical Instruments Revenue~$1.8B (5% growth)~$1.8B (1% growth)-400 bps deceleration
Pharma/Biotech End Marketmid-single digithigh single-digitAccelerated but vague
Academic/Governmentlow single digit declinelow single digit declineNo improvement despite budget clarity
Free Cash Flow (Full Year)$3.3B YTD through Q3$6.34B guidance implies $3.0B in Q4Massive Q4 FCF assumption required
2026 Organic Growth Guidance3-6% framework for '26-'273-4% for 2026Lowered to bottom of range

Accountability tracked

8 new promises made5 narrative shifts flagged7 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full TMO Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.